Antimicrobial Wound Care
Defeating biofilm Accelerating healing
Health Canada Authorized
The Challenge
The wound care system is failing patients
Persistent biofilm and infection continue to delay healing, while conventional treatment often increases burden without consistently improving outcomes.
Chronic wounds affected by biofilm.[01]
A lower-limb amputation occurs globally due to diabetes.[02]
Five-year mortality following a diabetic foot ulcer. [03]
Average treatment burden per DFU episode in the US.[04]
The ComBatic™ Platform
A new class of antimicrobial. Built differently
ComBatic™ is built on a synergistic combination of plant-based small molecules and inorganic salts. Unlike conventional antimicrobials that attack a single pathway, ComBatic™ acts simultaneously across four bacterial processes — cell membrane disruption, Fe–S cluster interference, reactive oxygen species (ROS) pathway disruption, and sulfur homeostasis targeting — making resistance development significantly less likely.
Broad-spectrum
Effective against bacteria, fungi, and resistant strains
Antibiofilm
Disrupts and clears mature biofilm in 2–5 minutes
Anti-inflammatory
Elevates glutathione (GSH), a natural antioxidant
Low resistance risk
Multi-target mechanism limits AMR development
01
Cleanse & Disrupt
ComBatic™ Wound Lavage: Apply the lavage solution to irrigate the wound. No scraping. No bleeding. No trauma to surrounding tissue.
02
Protect & Heal
ComBatic™ Wound Hydrogel Healing Matrix: Apply the hydrogel directly to the debrided wound. Sustains antimicrobial activity while maintaining an optimal moist healing environment to accelerate tissue regeneration.
Our Products
A Complete Wound Care System
ComBatic™ Antimicrobial Wound Lavage Spray
- $16.99
- $16.99
- Unit price
- per
ComBatic™ Antimicrobial Wound Lavage
- $14.99
- $14.99
- Unit price
- per
ComBatic™ Antimicrobial Wound Hydro-Gel
- $19.99
- $19.99
- Unit price
- per
ComBatic™
Engineered for real outcomes
Clinically developed, non-antibiotic healing support to reduce infection risk and improve patient outcomes.
Effective against 17 WHO priority pathogens
Broad-spectrum action against Gram-positive, Gram-negative bacteria, fungi, and biofilm.[05]
Accelerated wound closure in an infected preclinical wound model
In an MRSA-infected mouse wound model, ComBatic-treated wounds reached 96.9% closure by Day 9 compared with 86.7% with Prontosan.[06]
Antibiotic-Free
No risk of resistance. Safe for repeated use.[07]
Safe & Skin-Friendly
Gentle, non-toxic, and suitable for regular application.[08]
Clinical Evidence & Competitive Advantage
Proven performance. Measurable outcomes
▶
Latest News
Ready when you are
Transform wound care outcomes today
Clinically validated solutions designed to disrupt biofilms, reduce infection, and support faster recovery
References
[01] Malone M, Bjarnsholt T, McBain AJ, et al. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. Journal of Wound
Care. 2017;26(1):20–25. PubMed
[02] International Diabetes Federation. Complications of diabetes. “A lower limb is lost to diabetes somewhere in the world every 30 seconds.” Updated May 2026. IDF Source
[03] Chen L, Sun S, Gao Y, Ran X. Global mortality of diabetic foot ulcer: a systematic review and meta-analysis of observational studies. Diabetes, Obesity and Metabolism.
2023;25(1):36–45. PubMed
[04] Stockl K, Vanderplas A, Tafesse E, Chang E. Costs of lower-extremity ulcers among patients with diabetes. Diabetes Care. 2004;27(9):2129–2134. PubMed
[05] Broad-spectrum antimicrobial activity: MHCombiotic Published Data Addendum, Fig. 3. Supporting background: Pormohammad A, Monych NK, Ghosh S, Turner DL, Turner RJ. Nanomaterials in Wound Healing and Infection Control. Antibiotics. 2021;10(5):473.
[06] Preclinical wound-healing performance: MHCombiotic Published Data Addendum, Figs. 6–7, MRSA mouse wound model.
[07] Resistance development: Pormohammad A, Greening D, Turner RJ. Synergism inhibition and eradication activity of silver nitrate/potassium tellurite combination against Pseudomonas aeruginosa biofilm. Journal of Antimicrobial Chemotherapy. 2022;77(6):1635–1644. doi:10.1093/jac/dkac094.
[08] Biocompatibility: MHCombiotic Published Data Addendum, Tables 2–3; ISO 10993 biocompatibility testing conducted by Geneva Laboratories under GLP/GMP.
- Choosing a selection results in a full page refresh.